The global advanced therapy medicinal products (ATMP) CDMO market was valued at USD 8.16 Billion in 2025, driven by the rising number of clinical trials for ATMPs across the globe. It is expected to grow at a CAGR of 15.30% during the forecast period of 2026-2035, and attain a market value of USD 33.88 Billion by 2035.
Base Year
Historical Period
Forecast Period
In July 2023, the US FDA approved NTLA-2001, the first CRISPR-based gene therapy for treating transthyretin amyloidosis with cardiomyopathy in vivo. Such approvals are expected to boost the demand for CDMO services.
In December 2023, the US FDA authorized two gene-based therapies for sickle cell disease. This reflects rapid advancements in gene therapy treatments, which are poised to support market growth in the coming years.
Strong regulatory support from health authorities and ongoing research and development efforts are likely to elevate the market value in the forecast period.
Compound Annual Growth Rate
15.3%
Value in USD Billion
2026-2035
*this image is indicative*
Advanced therapy medicinal products CDMOs specialize in providing innovative cell, gene, and tissue-related treatments such as gene therapies, cell therapies, and tissue-engineered products. They offer a variety of services, including process development, manufacturing, production, and regulatory assistance, to accelerate pharmaceutical companies' entry into the market.
Rising Number of Clinical Trials for ATMPs to Drive the Market Growth
The increasing number of clinical trials is fueling market growth, with 3,579 therapies in development by Q1 2022, led by CAR-T cell treatments. The gene cell therapy pipeline has increased by 16% since the first quarter of 2021, with 98% of CAR-T cell treatments in the development phase for cancer indications.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Phase
Market Breakup by Indication
Market Breakup by Region
Market Segmentation Based on the Product to Witness Growth
Based on the product, the market is divided into cell therapy, gene therapy, and others. The gene therapy sector is leading because of substantial funding, robust clinical trial activity, and a variety of therapies being developed for diseases such as neurological, cancer, cardiovascular, blood, and infectious diseases.
The market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is expected to lead the market share in the forecast period owing to the rising popularity of outsourcing services and growing awareness of advanced therapies.
The key features of the market report include patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Rentschler Biopharma is a contract development and manufacturing organization (CDMO) that is actively engaged in developing and producing biopharmaceuticals. In September 2024, a new lentiviral vector manufacturing toolbox for advanced therapies was launched by the CDMO in the UK. This package comprises process development, cGMP manufacturing, and regulatory assistance.
AGC Biologics provides various cell therapy options for advanced therapy medicinal products (ATMPs), such as gene and cell therapies. The company is focused on producing protein-based biologicals and advanced therapies such as cell therapy, viral vectors, and mammalian and microbial cell therapy.
Celonic Group provides development and manufacturing services for new biological entities, biosimilars, cell therapy, and gene-associated services. They are involved in the market with a facility in Switzerland's life science park rheintal, offering development and GMP production capabilities for various therapies, vaccines, and biopharmaceuticals.
Bio Elpida, a Biotechnology contract manufacturing company in Lyon, France, specializes in advanced therapy medicinal products. Their expertise includes R&D, pharmaceutical development, and GMP manufacturing for innovative cell therapies. They aim to advance European biotechnologies for chronic diseases.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market are Cell Therapy Catapult Ltd., Catalent, Inc., Lonza, WuXi Advanced Therapies, and Minaris Regenerative Medicine.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Phase |
|
| Breakup by Indication |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share